13 research outputs found
Generating Focussed Molecule Libraries for Drug Discovery with Recurrent Neural Networks
In de novo drug design, computational strategies are used to generate novel
molecules with good affinity to the desired biological target. In this work, we
show that recurrent neural networks can be trained as generative models for
molecular structures, similar to statistical language models in natural
language processing. We demonstrate that the properties of the generated
molecules correlate very well with the properties of the molecules used to
train the model. In order to enrich libraries with molecules active towards a
given biological target, we propose to fine-tune the model with small sets of
molecules, which are known to be active against that target.
Against Staphylococcus aureus, the model reproduced 14% of 6051 hold-out test
molecules that medicinal chemists designed, whereas against Plasmodium
falciparum (Malaria) it reproduced 28% of 1240 test molecules. When coupled
with a scoring function, our model can perform the complete de novo drug design
cycle to generate large sets of novel molecules for drug discovery.Comment: 17 pages, 17 figure
Recommended from our members
Opportunities and obstacles for deep learning in biology and medicine
Deep learning describes a class of machine learning algorithms that are capable of combining raw inputs into layers of intermediate features. These algorithms have recently shown impressive results across a variety of domains. Biology and medicine are data-rich disciplines, but the data are complex and often ill-understood. Hence, deep learning techniques may be particularly well suited to solve problems of these fields. We examine applications of deep learning to a variety of biomedical problems—patient classification, fundamental biological processes and treatment of patients—and discuss whether deep learning will be able to transform these tasks or if the biomedical sphere poses unique challenges. Following from an extensive literature review, we find that deep learning has yet to revolutionize biomedicine or definitively resolve any of the most pressing challenges in the field, but promising advances have been made on the prior state of the art. Even though improvements over previous baselines have been modest in general, the recent progress indicates that deep learning methods will provide valuable means for speeding up or aiding human investigation. Though progress has been made linking a specific neural network's prediction to input features, understanding how users should interpret these models to make testable hypotheses about the system under study remains an open challenge. Furthermore, the limited amount of labelled data for training presents problems in some domains, as do legal and privacy constraints on work with sensitive health records. Nonetheless, we foresee deep learning enabling changes at both bench and bedside with the potential to transform several areas of biology and medicine
Artificial intelligence for natural product drug discovery
Developments in computational omics technologies have provided new means to access the hidden diversity of natural products, unearthing new potential for drug discovery. In parallel, artificial intelligence approaches such as machine learning have led to exciting developments in the computational drug design field, facilitating biological activity prediction and de novo drug design for molecular targets of interest. Here, we describe current and future synergies between these developments to effectively identify drug candidates from the plethora of molecules produced by nature. We also discuss how to address key challenges in realizing the potential of these synergies, such as the need for high-quality datasets to train deep learning algorithms and appropriate strategies for algorithm validation
Artificial intelligence for natural product drug discovery
Developments in computational omics technologies have provided new means to access the hidden diversity of natural products, unearthing new potential for drug discovery. In parallel, artificial intelligence approaches such as machine learning have led to exciting developments in the computational drug design field, facilitating biological activity prediction and de novo drug design for molecular targets of interest. Here, we describe current and future synergies between these developments to effectively identify drug candidates from the plethora of molecules produced by nature. We also discuss how to address key challenges in realizing the potential of these synergies, such as the need for high-quality datasets to train deep learning algorithms and appropriate strategies for algorithm validation. [Abstract copyright: © 2023. Springer Nature Limited.